Acutus Medical Inc (AFIB)

[subslover]

The run-up to $2.16 was simply AMAZING! :)

[glenn1919]

AFIB................................https://stockcharts.com/h-sc/ui?s=afib&p=W&b=5&g=0&id=p86431144783

[subslover]

Acutus Medical Announces CEO Appointment and Preliminary Second Quarter Revenue Results
July 21 2022 - 06:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that David Roman has been appointed President and Chief Executive Officer, and member of the Board of Directors, effective immediately. The Company also announced preliminary second quarter revenue results.
“Since being appointed interim CEO, David has hit the ground running with an intense focus on reinvigorating the Company’s strategy, driving operational improvements, and successfully completing the first close of our left-heart access portfolio sale to Medtronic and debt refinancing,” said Scott Huennekens, Chairman of the Acutus Board of Directors. “As the Board considered the needs of the Company, we determined that this focus as well as David’s performance over the past two months made him the right person to lead Acutus moving forward. In addition, David has demonstrated strong and engaging leadership with the senior management team as well as the Board, and we are confident in David’s ability to drive long-term growth and value creation at Acutus.”

Mr. Roman said, “Acutus benefits from a dedicated and passionate team, and as CEO I am excited to continue driving the adoption of our electrophysiology mapping and therapy solutions as well as improving our operational and financial performance. We have a tremendous amount of opportunity ahead of us, and I am confident in our ability to execute on our plans and maintain positive momentum in 2022 and beyond.”

Mr. Roman, who joined the Company as Chief Financial Officer in March 2021, has also been serving as Interim Chief Executive Officer since May 13, 2022. He will continue as Chief Financial Officer until a replacement is determined.

Preliminary Second Quarter Revenue
The Company expects second quarter 2022 revenues of approximately $4.0-$4.1 million compared to $4.7 million in the second quarter of 2021 and $3.7 million in the first quarter of 2022.

“We are pleased with the progress in our business through the second quarter. Our deliberate focus on procedure volumes and utilization is gaining momentum, as we achieved another quarter of record procedure volumes with growth on a both a sequential and year-over-year basis,” said Mr. Roman. “In addition, we are starting to see the benefits of our cost improvement programs with a significant decline in our second quarter 2022 cash burn when compared to the first quarter of 2022. We look forward to providing additional updates on our second quarter 2022 earnings call in August.”

The preliminary unaudited revenue results described in this press release are estimates only and subject to revision until we report our full financial results for the second quarter 2022 during our earnings announcement planned for August.

About Acutus Medical, Inc.
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and

[subslover]

Holy ask kicking! Up 21% today and closed $1.39 it's just so sweet when you're riding a stock from 0 .47 in just a few weeks.

[subslover]

I'm happy with today's close of $1.16 up 7.4% and were steadily going higher each week. Hoping for news soon.

[subslover]

A very nice day closing up 10% at $1,10. More on the way! :)

[subslover]

Thank you for that info cash4. I feel we will get there over time while more great news hits.

[cash4]

Analysts have set a mean price target of $3.32. This target is 287.04% above the current price.



https://www.chartmill.com/stock/quote/AFIB/analyst-ratings

[subslover]

I agree! Looking for new stepping stones soon!

[duderaja]

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:01 ET | Source: Acutus Medical, Inc.





...
CARLSBAD, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on July 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 2 individuals hired by Acutus in June 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received, in the aggregate, 6,000 restricted stock units (“RSUs”). One-fourth of the RSUs granted to each employee will vest yearly on each anniversary of the grant date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the grant date, in each case, subject to each such employee’s continued employment with Acutus on such vesting date.

About Acutus Medical, Inc.
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “will,” “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of its products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase the Company’s systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally, including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the coronavirus (COVID-19) pandemic and Acutus’ response to it, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.


Investor Contact: Media Contact:
Caroline Corner Levitate
Westwicke ICR [phone]
D: 415-202-5678 [e-mail]
[e-mail]

[nonsequetor]

This could become interesting...

[duderaja]

Analysts rating: 1 buy, 2 Holds, no underweights or sell ratings. This was before the FDA approved them for commercial launch of AcQCross Line Extension. This can't do anything but go up once profit takers are out of the way, which may already be about over. Look out above. IMO

[cash4]

Because it already saw its bottom and we have great news, this stock needs to stay above a dollar, that's why.

[Pt3]

Why

[cash4]

Tomorrow $AFIB will open at $2.50 and close by $5 on Friday, hold on to your shares, 15% shorts in $AFIB.

[herbied47]

Nice ride!

[subslover]

WEEEEEEEEEEEEEEEEEEEEEEEE GETTING NEAR STRATUSPHERE.

[INFINITI]

How high can she go

[INFINITI]

Looks good here

[Invest-in-America]

AFIB: See ya-all up on the MOON today, Folks!!!

https://www.marketscreener.com/quote/stock/ACUTUS-MEDICAL-INC-110535819/news/Acutus-Medical-Announces-FDA-Clearance-Commercial-Launch-of-AcQCross-trade-Line-Extension-Compatib-40833065/

[subslover]

Acutus Medical Announces FDA Clearance, Commercial Launch of AcQCross™ Line Extension Compatible with Watchman™ Delivery System
Innovative Transseptal Access System Is First and Only to Feature Integrated Dilator and Needle to Reduce Exchanges
June 27, 2022 06:00 ET | Source: Acutus Medical, Inc.




...
CARLSBAD, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the commercial launch of an expanded suite of left-heart access products to now include the AcQCross™ Qx system for use with the TruSeal (TM) and FXD(TM) delivery system for the Watchman™ LAAC Device.

Gaining access to the left atrium requires physicians to cross the septum, a multi-step process that often involves the exchange of wires and needles while trying to achieve the proper angle and location on the septum. AcQCross is the first and only transseptal system engineered with an integrated needle and dilator to reduce these exchanges. US Left-atrial appendage closure procedures are expected to total over 50,000 in 2022, according to the Millennium Research Group. With this clearance, Acutus now offers sheath-compatible transseptal access devices that cover 409,000 electrophysiology and structural heart procedures in the US.

“Crossing the septum at the proper location is important when doing any left-sided heart procedure, but it can be especially critical to the success of delivering Watchman to the left atrial appendage,” said Dr. Tom Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Director, Structural Heart Program and Cardiovascular Research, Tucson Medical Center, Tucson, Arizona. “With AcQCross, I can easily reposition without withdrawing or exchanging needles or wires, so its new compatibility with Watchman has made my procedures much safer for my patients and far more efficient for me and my team.”

AcQCross features an array of catheters that are length-, diameter- and tip-matched and designed to lock into the hub of market-leading sheaths used in the vast majority of left-heart procedures, including delivery of the Watchman. With the expanded product offering, physicians can utilize AcQCross with their preferred sheaths during virtually any left-heart access procedure.

“The AcQCross system provides interventional cardiologists and electrophysiologists with unique benefits of broad compatibility with market-leading access sheaths while also enhancing procedure versatility and workflow,” said David Roman, interim Chief Executive Officer and Chief Financial Officer, Acutus Medical. “The expanded AcQCross product line allows us to bring this innovative technology to a wider range of procedure categories that should drive sustained growth in this portfolio.”

AcQCross and its entire line of catheters are commercially available in the United States. For more information, visit www.acutusmedical.com/us/.

About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Sale of Left-Heart Access Portfolio to Medtronic
On April 27, 2022, Acutus announced a definitive agreement to sell its left-heart access portfolio to Medtronic. Under the terms of the agreement, Medtronic will make an upfront cash payment to Acutus of $50 million upon the initial closing of the transaction, subject to the satisfaction of customary closing conditions, including expiration or early termination of all applicable waiting periods (and any extensions thereof) under applicable antitrust laws, and the closing of the Company’s debt refinancing, as well as contingent consideration payments over time based on the achievement of certain milestones and future sales.

[TrendTrade2016]

AFIB play the FDA

[nonsequetor]

CFO got his 100K SH

[nonsequetor]

equity awards were approved...

[nonsequetor]

Down when everyone else is up 5-6% this morning.

[nonsequetor]

.90 target

[nonsequetor]

This is a bargain under a buck

[nonsequetor]

Sentiment cooling or patiently waiting?

[nonsequetor]

AFIB seems to be gravitating toward the gap

[nonsequetor]

What happened to all the interest in AFIB?

[doogdilinger]

They should be outlawed as it's total dirtball manipulation and I'm glad they failed to get this one delisted. Proof positive that karma is a very powerful force and works right buddy cheers!

[subslover]

Me doogi, when you get a chance you should check out all the bogus ambulance chaser class-action suits. All because peps like Johnnyboy the dick bought too high. If I had my way these bozos would be dis bared for being the lowest form of scum on the planet. Even a leach has a little class. lol

[doogdilinger]

Agreed brotha, no small feat for them to totally destroy the idiotic manipulative forces that were foolishly trying to keep them under a buck too!

Karma works beautifully as always:)

[subslover]

Personally and IMHO this stock is better than GERN. We will see............... :)

[doogdilinger]

Agreeeeeeeeeed brotha!!! Happy Days are here again>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[subslover]

Yes, doogi, needs to close at $1.00 or above tomorrow. Keep an eye out for news me bucko! :)

[doogdilinger]

Couple more days above +$1 easy peasy right subs buddy!!!

[subslover]

And look at the aftermarket movement trading @ $1.34 or 11.4% higher while the entire stock market had yet another miserable day! Manipulators will are defeated my ole doogi brother

[doogdilinger]

Congratulations INFINITI...happy days are finally here again whew>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[doogdilinger]

This one's already defeated the idiots who tried manipulating it and holdin' it under $1 right subs buddy!!! The boys are back in town woooooooooooooohoooooooooooooooo

[subslover]

And with only 28 mil shares outstanding! How amazing is that?

[doogdilinger]

AFIB destined for biotech greatness folks>>>$$$$$$$$$$$$$$$$$$$$$$$$

[doogdilinger]

AFIB is finally beating the manipulators at their own dirty games subs buddy wooooooooooohoooooooooooooo

[subslover]

Yes my doogi very much expected after the huge day we had yesterday and look how she perked higher once the Proxy statement was posted :) https://ih.advfn.com/stock-market/NASDAQ/acutus-medical-AFIB/stock-news/87948213/proxy-statement-definitive-def-14a

Although a long read it's important to take some time to see the kind of medical breakthrough we have waiting in the wings.

[doogdilinger]

Little expected & healthy profit takin' dip after an incredibly explosive day yesterday subs buddy!

[subslover]

Acutus Medical to Announce First Quarter 2022 Financial Results
April 27 2022 - 04:01PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing [phone] for domestic callers or [phone] for international callers, using conference ID: 3455233. The live webinar of the call may be accessed by visiting the Events section of the Acutus investor relations website at ir.acutusmedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.

About Acutus Medical, Inc.
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California

[INFINITI]

Looks good I’m in

[doogdilinger]

Gotta luv it subs buddy! BOOM goes the dynamite once again>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[subslover]

Acutus Medical Announces Agreements to Fund Strategic Growth Priorities

https://seekingalpha.com/news/3827486-afib-stock-surges-on-deal-with-medtronic

[doogdilinger]

KABOOM!!!